Studies on Prodrugs. IV. Preparation and Characterization of N-(5-Substituted 2-oxo-l,3-dioxol-4-yl)methyl Norfloxacin

Fumio Sakamoto, Shoji Ikeda, Hirosato Kondo, Goro Tsukamoto

研究成果: ジャーナルへの寄稿記事

26 引用 (Scopus)

抄録

As a new type of norfloxacin (NFLX) prodrug, N-(5-substituted 2-oxo-l, 3-dioxol-4-yl)methyl NFLXs were designed. These N-masked NFLXs were prepared and confirmed to produce higher NFLX levels in blood than NFLX itself after oral administration to mice. N-(5-Methyl-2-oxo-l,3-dioxol-4-yl)methyl NFLX was found to be smoothly hydrolyzed in mouse blood in vitro, and when administered orally, gave about 5-fold higher blood levels of NFLX than NFLX itself. Thus, the (5-methyl-2-oxo-l,3-dioxol-4-yl)methyl group was confirmed to function as an amine-type promoiety.

元の言語英語
ページ(範囲)4870-4877
ページ数8
ジャーナルChemical and Pharmaceutical Bulletin
33
発行部数11
DOI
出版物ステータス出版済み - 1 1 1985

Fingerprint

Norfloxacin
Prodrugs
Blood
Amines
Oral Administration

All Science Journal Classification (ASJC) codes

  • Chemistry(all)
  • Drug Discovery

これを引用

Studies on Prodrugs. IV. Preparation and Characterization of N-(5-Substituted 2-oxo-l,3-dioxol-4-yl)methyl Norfloxacin. / Sakamoto, Fumio; Ikeda, Shoji; Kondo, Hirosato; Tsukamoto, Goro.

:: Chemical and Pharmaceutical Bulletin, 巻 33, 番号 11, 01.01.1985, p. 4870-4877.

研究成果: ジャーナルへの寄稿記事

@article{d17514e6551842fda6922cd82f195f13,
title = "Studies on Prodrugs. IV. Preparation and Characterization of N-(5-Substituted 2-oxo-l,3-dioxol-4-yl)methyl Norfloxacin",
abstract = "As a new type of norfloxacin (NFLX) prodrug, N-(5-substituted 2-oxo-l, 3-dioxol-4-yl)methyl NFLXs were designed. These N-masked NFLXs were prepared and confirmed to produce higher NFLX levels in blood than NFLX itself after oral administration to mice. N-(5-Methyl-2-oxo-l,3-dioxol-4-yl)methyl NFLX was found to be smoothly hydrolyzed in mouse blood in vitro, and when administered orally, gave about 5-fold higher blood levels of NFLX than NFLX itself. Thus, the (5-methyl-2-oxo-l,3-dioxol-4-yl)methyl group was confirmed to function as an amine-type promoiety.",
author = "Fumio Sakamoto and Shoji Ikeda and Hirosato Kondo and Goro Tsukamoto",
year = "1985",
month = "1",
day = "1",
doi = "10.1248/cpb.33.4870",
language = "English",
volume = "33",
pages = "4870--4877",
journal = "Chemical and Pharmaceutical Bulletin",
issn = "0009-2363",
publisher = "The Pharmaceutical Society of Japan",
number = "11",

}

TY - JOUR

T1 - Studies on Prodrugs. IV. Preparation and Characterization of N-(5-Substituted 2-oxo-l,3-dioxol-4-yl)methyl Norfloxacin

AU - Sakamoto, Fumio

AU - Ikeda, Shoji

AU - Kondo, Hirosato

AU - Tsukamoto, Goro

PY - 1985/1/1

Y1 - 1985/1/1

N2 - As a new type of norfloxacin (NFLX) prodrug, N-(5-substituted 2-oxo-l, 3-dioxol-4-yl)methyl NFLXs were designed. These N-masked NFLXs were prepared and confirmed to produce higher NFLX levels in blood than NFLX itself after oral administration to mice. N-(5-Methyl-2-oxo-l,3-dioxol-4-yl)methyl NFLX was found to be smoothly hydrolyzed in mouse blood in vitro, and when administered orally, gave about 5-fold higher blood levels of NFLX than NFLX itself. Thus, the (5-methyl-2-oxo-l,3-dioxol-4-yl)methyl group was confirmed to function as an amine-type promoiety.

AB - As a new type of norfloxacin (NFLX) prodrug, N-(5-substituted 2-oxo-l, 3-dioxol-4-yl)methyl NFLXs were designed. These N-masked NFLXs were prepared and confirmed to produce higher NFLX levels in blood than NFLX itself after oral administration to mice. N-(5-Methyl-2-oxo-l,3-dioxol-4-yl)methyl NFLX was found to be smoothly hydrolyzed in mouse blood in vitro, and when administered orally, gave about 5-fold higher blood levels of NFLX than NFLX itself. Thus, the (5-methyl-2-oxo-l,3-dioxol-4-yl)methyl group was confirmed to function as an amine-type promoiety.

UR - http://www.scopus.com/inward/record.url?scp=0022377168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022377168&partnerID=8YFLogxK

U2 - 10.1248/cpb.33.4870

DO - 10.1248/cpb.33.4870

M3 - Article

C2 - 3830420

AN - SCOPUS:0022377168

VL - 33

SP - 4870

EP - 4877

JO - Chemical and Pharmaceutical Bulletin

JF - Chemical and Pharmaceutical Bulletin

SN - 0009-2363

IS - 11

ER -